Suzuki Nobumi, Odawara Nariaki, Fujisawa Gota, Ishibashi Rei, Hata Masahiro, Oya Yukiko, Tamada Kenji, Hayashi Takeshi, Abe Sohei, Miyakawa Yu, Hayakawa Yoku, Shinozaki-Ushiku Aya, Ushiku Tetsuo, Boku Narikazu, Fujishiro Mitsuhiro
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Department of Pathology, The University of Tokyo Hospital, Japan.
Intern Med. 2025 Jan 1;64(1):101-107. doi: 10.2169/internalmedicine.3155-23. Epub 2024 Jun 6.
Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.
曲妥珠单抗德曲妥珠单抗（T-DXd）作为人表皮生长因子受体2（HER2）阳性晚期胃癌和胃食管交界腺癌的三线或更后线化疗药物，已显示出显著疗效。然而，它可能会引起肺炎，其在罕见组织学类型如具有成肌母细胞分化的胃腺癌（GAED）中的疗效仍不明确。一名74岁的女性，患有不可切除的HER2阳性GAED并伴有肺转移，接受T-DXd作为五线化疗。由于药物性肺炎，在15个周期后停止治疗；然而，患者在未进行后续化疗或肺炎加重的情况下，持续完全缓解达14个月。T-DXd对HER2阳性GAED有效。
